scholarly journals Expression of Epidermal Growth Factor Receptor (EGF-R), Vascular Endothelial Growth Factor Receptor (VEGF-R) and Fibroblast Growth Factor Receptor (FGF-R) Systems in Porcine Oviduct and Endometrium during the Time of Implantation

2004 ◽  
Vol 50 (3) ◽  
pp. 269-278 ◽  
Author(s):  
Karin WOLLENHAUPT ◽  
Harald WELTER ◽  
Ralf EINSPANIER ◽  
Noboru MANABE ◽  
Klaus-Peter BRÜSSOW
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Fibroblast Growth Factor Receptor ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Fibroblast Growth ◽  
Epidermal Growth ◽  
Endothelial Growth Factor

Fortgeschrittenes medulläres Schilddrüsenkarzinom: Vandetanib verbessert das progressionsfreie Überleben

2012 ◽  
Vol 03 (02) ◽  
pp. 93-92
Author(s):  
Alexander Kretzschmar
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Phase Iii ◽  
Vascular Endothelial ◽  
Medulläres Schilddrüsenkarzinom ◽  
Epidermal Growth ◽  
Endothelial Growth Factor

Vandetanib ist ein oraler Hemmer des RET-Kinase-, VEGF (Vascular Endothelial Growth Factor Receptor)- und EGFR (Epidermal Growth Factor Receptor)-Signalwegs. In einer zulassungsrelevanten, randomisierten, doppelblinden, placebokontrollierten Phase- III-Studie verlängerte der Tyrosinkinasehemmer das progressionsfreie Überleben (PFS) signifikant länger als Placebo.

Sign in / Sign up

Export Citation Format

Share Document